710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors - John Powderly; Jae Lyun Lee; Jung-Yun Lee; Byoung Chul Cho; Kyoung-Ho Pyo; Soohyeon Lee; Dong Kim; Myoung Ho Jang; Byoung Yong Shim; Sang Joon Shin; Nari Yun; Mina Ham; et al. (Journal for ImmunoTherapy of Cancer, 2023)